Dr. Reddy's Laboratories Limited
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Erez Israeli
- Full Time Employees
- 27,527
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 8-2-337, Road No. 3 Hyderabad TS India 500034
- IPO Date
- Apr 11, 2001
- CIK
- 0001135951
- Website
- drreddys.com
- Similar Companies
- Business
- Dr. Reddy's Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Hyderabad, India, and founded in 1984 that develops, manufactures, and markets a broad portfolio of products including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, differentiated formulations, over-the-counter (OTC) medicines, and innovative prescription drugs across therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, dermatology, anti-infectives, and critical care; key offerings encompass over 190 formulations like omeprazole (Omez), rabeprazole (Razo), rituximab biosimilars, toripalimab for nasopharyngeal carcinoma, lenacapavir for HIV under license from Gilead Sciences, and APIs including abiraterone acetate, canagliflozin, ciprofloxacin hydrochloride, ramipril, ibuprofen, sertraline hydrochloride, and naproxen sodium. The company operates globally in over 66 countries with a strong emphasis on North America, Europe, India, Russia, emerging markets, and regions including China, Japan, Vietnam, Myanmar, and South Africa, serving patients, pharmacies, hospitals, and other pharmaceutical firms through vertically integrated facilities compliant with US FDA, EMA, and other regulators. In recent developments, Dr. Reddy's completed the acquisition of Haleon's global nicotine replacement therapy (NRT) portfolio excluding the US for GBP 458 million in September 2024 to bolster its OTC consumer healthcare business, entered a June 2025 collaboration with Alvotech to co-develop, manufacture, and commercialize a pembrolizumab (Keytruda) biosimilar for global markets sharing costs and responsibilities, expanded partnerships including with Advanz Pharma for additional biosimilars and with Nestle India via joint venture for capabilities enhancement, and launched products such as the first UK-approved bevacizumab biosimilar for multiple cancers, Skorolox (loxoprofen) in Russia, and a RSV preventive for infants in India while advancing complex injectables, cell/gene therapies, and patient support programs like Purple Health.
Company News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Arrowstreet Capital Limited Partnership Buys Shares of 102,643 Dr. Reddy’s Laboratories Ltd $RDY
DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)
RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)
Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)
U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO